Cargando…
Pharmacokinetic and metabolomic studies with a BIO 300 Oral Powder formulation in nonhuman primates
BIO 300, a pharmaceutical formulation of genistein, is being developed as a radiation countermeasure to treat hematopoietic acute radiation syndrome (H-ARS) and the delayed effects of acute radiation exposure (DEARE). Several studies have affirmed its safety and efficacy in alleviating the damaging...
Autores principales: | Li, Yaoxiang, Girgis, Michael, Jayatilake, Meth, Serebrenik, Artur A., Cheema, Amrita K., Kaytor, Michael D., Singh, Vijay K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356050/ https://www.ncbi.nlm.nih.gov/pubmed/35931769 http://dx.doi.org/10.1038/s41598-022-17807-7 |
Ejemplares similares
-
Comparative proteomic analysis of serum from nonhuman primates administered BIO 300: a promising radiation countermeasure
por: Girgis, Michael, et al.
Publicado: (2020) -
Pharmacokinetic and Metabolomic Studies with BIO 300, a Nanosuspension of Genistein, in a Nonhuman Primate Model
por: Cheema, Amrita K., et al.
Publicado: (2019) -
Microbiome study in irradiated mice treated with BIO 300, a promising radiation countermeasure
por: Cheema, Amrita K., et al.
Publicado: (2021) -
Analysis of the metabolomic profile in serum of irradiated nonhuman primates treated with Ex-Rad, a radiation countermeasure
por: Li, Yaoxiang, et al.
Publicado: (2021) -
Alterations in Tissue Metabolite Profiles with Amifostine-Prophylaxed Mice Exposed to Gamma Radiation
por: Cheema, Amrita K., et al.
Publicado: (2020)